Practice Bulletin No. 149: Endometrial cancer. Obstet Gynecol, 2015; 125(4):1006–1026.
3.
KuhleCL, KapoorE, SoodR, et al.Menopausal hormone therapy in cancer survivors: A narrative review of the literature. Maturitas, 2016; 92:86–96.
4.
The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 2022; 29(7):767–794.
5.
VillaP, BounousVE, AmarID, et al.Hormone Replacement Therapy in Post-Menopause Hormone-Dependent Gynecological Cancer Patients: A Narrative Review. J Clin Med, 2024; 13(5):1443.
6.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology for Uterine Neoplasms 3.7.2025. 2025.
7.
GormanM, ShihK. Updates in Hormone Replacement Therapy for Survivors of Gynecologic Cancers. Curr Treat Options Oncol, 2025; 26(3):179–186.
8.
SinnoAK, PinkertonJ, FebbraroT, et al.Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: A Society of Gynecologic Oncology (SGO) clinical practice statement: This practice statement has been endorsed by The North American Menopause Society. Gynecol Oncol, 2020; 157(2):303–306.
9.
BarakatRR, BundyBN, SpirtosNM, et al.; Gynecologic Oncology Group Study. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: A Gynecologic Oncology Group Study. J Clin Oncol, 2006; 24(4):587–592.
